Vadim S. Koshkin

MD

Genitourinary oncologist
Avid traveler and reader, Chicago sports fan and trivia buff

Dr. Vadim S. Koshkin is a genitourinary oncologist who specializes in caring for adults with bladder, prostate, kidney and testicular cancers. His personal enthusiasm for travel informs his approach to care, as he likes to hear about where his patients come from in order to better understand who they are.

In his research, Koshkin designs and carries out clinical trials of treatments for bladder and prostate cancers. He has a particular focus on the role of immunotherapy, or treatments that stimulate a patient's own immune system to help fight cancer. He also studies targeted treatments that are aimed against specific mutations in the DNA of tumor cells, which make these tumors more vulnerable to particular drugs. This allows for the delivery of personalized treatment based on individual characteristics of patients and their tumors.

After earning his medical degree at the University of Chicago Pritzker School of Medicine, Koshkin completed a residency in internal medicine at the University of Michigan. He then completed a fellowship in hematology and oncology at the Cleveland Clinic. He belongs to the American Society of Clinical Oncology, American Association for Cancer Research and Bladder Cancer Advocacy Network.

A history and trivia buff, Koshkin loves to read. He also follows soccer and Chicago sports teams in his free time.

  • Education

    University of Chicago Pritzker School of Medicine, 2012

  • Residencies

    University of Michigan, Internal Medicine, 2015

  • Fellowships

    Cleveland Clinic, Hematology/Oncology, 2018

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

  • Academic Title

    Associate Professor

Each cancer patient is unique and deserves unique care. This means extra attention to personal needs but also individualized attention to treatment.

Conditions I specialize in

Where I see patients (2)

    My reviews

    4.9

    Overall Experience
    192 Ratings
    About our process
    Aug 28, 2024
    Dr. Koshkin is a fabulous physician. Very caring, Knowledgeable and thorough In both his questions and answers
    Aug 07, 2024
    Always a positive experience.
    May 30, 2024
    Very knowledgeable and informative
    Mar 18, 2024
    How can I be critical of someone who has helped me live 8+ years with Stage 4 prostate cancer. I have not only lived longer than I thought, but my quality of life could not be better, for my age.
    Mar 06, 2024
    I am extremely happy with the discussion process and followed with a written summary of next steps.
    Jan 05, 2024
    Dr Koshkin was very patient with our questions and concerns.
    Oct 05, 2023
    Very knowledgeable, open, kind and caring
    Sep 09, 2023
    Dr Koshkin is wonderful.
    Jul 28, 2023
    Vadim Koshkin is the best!
    Jul 16, 2023
    As always, the Dr. And his Fellow were courteous and professional.
    Jul 07, 2023
    Great job
    Jul 02, 2023
    Dr, Koshkin is first class in every way!
    Jun 30, 2023
    Absolute confidence in Dr. Koshkin's medical care and concern for patient's well being.
    May 25, 2023
    I don't know what the outcome was of my visit. I need to no what the Good and the bad please.
    Apr 08, 2023
    Very good job
    Apr 05, 2023
    Dr Koshkin is Excellent!!
    Jan 30, 2023
    Dr, Koshin has always been and continues to be a fantastic physician for me. He treated me successfully for my urethral cancer, which included 6 months of chemotherapy. He deserves the highest marks possible.
    Jan 05, 2023
    I have had the very best of attention- from Dr koshkin
    Dec 23, 2022
    Great job

    Selected research

    See all research
    Decorative Caduceus

    Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer ...

    The time from randomization to first documentation of disease progression per RECIST v1.1 by BICR, or to death due to any cause.

    Recruiting

    Decorative Caduceus

    A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HE...

    The proportion of participants with confirmed complete response (CR) or partial response (PR) according to RECIST v1.1

    Recruiting

    Decorative Caduceus

    Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate C...

    If two or more patients in a cohort experience a dose-limiting toxicity (DLT), then the maximum tolerated dose (MTD)has been exceeded. The previous dose level will be considered the MTD and the recommended phase 2 dose. Per Invest...

    Recruiting

    Decorative Caduceus

    Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Canc...

    The RP2D is the last dose cohort at which no more than one instance of a dose limiting toxicity (DLT) is observed among 6 participants treated. If the maximum tolerated dose (MTD) cannot be determined due to lack of DLT during the...

    Recruiting

    Decorative Caduceus

    HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

    The proportion of participants who have a best overall response (BOR) based on complete response (CR) or partial response (PR). The BOR for each participant is the best response (radiographically documented and measurable disease ...

    Recruiting

    Contact me

    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF are covered by every insurance plan.
    This provider is employed by a medical group affiliated with UCSF.

    Share